Innoviva, Inc.

Innoviva, Inc. ( Innoviva , the Company , the Registrant or we and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ( IST ), and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited ( GSK ), including RELVAR /BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI ) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI ). Under the Long-Acting Beta-2 Agonist ( LABA ) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR /BREO ELLIPTA as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO ELLIPTA , which tier upward at a range from 6.5% to 10%.